Company profile

BioLytical Laboratories

biolytical.comHeadquarters: United States
51-200 employeesProduct Vendor
BioLytical Laboratories logo

Primary focus

Manufacturer of rapid point-of-care in vitro diagnostic tests focused on infectious diseases.

Why it’s included

The company develops and manufactures multiple rapid point-of-care lateral-flow and multiplex immunoassays for infectious-disease antigen and antibody detection, as evidenced by named products such as the 'iStatis lateral-flow platform' and 'INSTI Multiplex Ab' for HIV, hepatitis, syphilis, and COVID-19.

Relevant capabilities

  • Proprietary flow-through immunoassay platform
  • Lateral-flow immunoassay platform development
  • Rapid point-of-care diagnostic test development
  • Antibody and antigen immunoassay design (IgG/IgM)
  • Multiplex assay development
Commercial sectorInstrument-free lateral flow and rapid tests
Technology classesConventional antibody lateral flow and rapid immunoassays

Relevant commercial products

  • iStatis lateral-flow platform
  • INSTI Multiplex Ab
  • Multiplex HIV-1/2 and Syphilis Antibody Test
  • iStatis COVID-19 Antigen Test (professional)
  • INSTI 4 HCV Antibody Test

Relevant patents

1 family, 1 publication
  • Methods and rapid test kits facilitating epidemiological surveillance US-11011278-B1

← Back to what’s inside this report